2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10107
    TAT-PAK18 R192A
    		Control
    TAT-PAK18 R192A is an inactive Tat-Pak peptide. TAT-PAK18 R192A does not have any effect in the translocation of Rac1 triggered by any of the interrogated proteins.
    TAT-PAK18 R192A
  • HY-182883
    KRASG12C IN-20
    		Inhibitor
    KRASG12C IN-20 is an orally potent KRASG12C inhibitor with an EC50 of 3.9 nM. KRASG12C IN-20 covalently modifies KRASG12C in its inactive GDP-bound state and locks it to block oncogenic signal transduction. KRASG12C IN-20 exhibits significant activity in lung adenocarcinoma xenograft models. KRASG12C IN-20 can be used for research related to lung adenocarcinoma.
    KRASG12C IN-20
  • HY-176250
    KRAS-IN-43
    		Inhibitor
    KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC50 values of 0.15 μM, 0.14 μM, and 0.47 μM against KRASG12V, KRASG12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer).
    KRAS-IN-43
  • HY-179452
    KRAS G13D-IN-2
    		Inhibitor
    KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 μM (HCT-116G13D) and 2.16 μM (HCT-15G13D). KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRASG13D-mutant colorectal cancer research.
    KRAS G13D-IN-2
  • HY-169311
    KRAS inhibitor-37
    		Inhibitor
    KRAS inhibitor-37 (compound 2) is a potent KRAS inhibitor with KDs of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC50s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research.
    KRAS inhibitor-37
  • HY-182411
    KRAS-IN-56
    		Inhibitor
    KRAS-IN-56 (Compound 18) is a KRAS inhibitor with an EC50 of 33 μM. KRAS-IN-56 inhibits the interaction between GTP-KRAS and SOS1. KRAS-IN-56 induces a decrease in p-ERK levels. KRAS-IN-56 can be used in research related to lung cancer.
    KRAS-IN-56
  • HY-179058
    JOSD2-IN-1
    		Inhibitor
    JOSD2-IN-1 (Compound 31) is a covalent JOSD2 inhibitor with an IC50 value of 1.95 μM. JOSD2-IN-1 inhibits JOSD2, thereby down-regulating KRAS expression. JOSD2-IN-1 exhibits significant anti-proliferative activity against HCT116 cells. JOSD2-IN-1 can be used for research on colorectal cancer.
    JOSD2-IN-1
  • HY-162969
    MRTF-A-IN-2
    		Inhibitor
    MRTF-A-in-2 (Compound 16) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging.
    MRTF-A-IN-2
  • HY-180920
    KRAS G12D-IN-36
    		Inhibitor
    KRAS G12D-IN-36 (Compound 53a) is a highly selective and orally active KRAS-G12D inhibitor with an IC50 of 1.63 nM. KRAS G12D-IN-36 effectively inhibits p-ERK with an IC50 of 8.4 nM. KRAS G12D-IN-36 shows potent anti-proliferative activity against AsPC-1 cells. KRAS G12D-IN-36 can be used for research on pancreatic cancer.
    KRAS G12D-IN-36
  • HY-162976
    KRAS inhibitor-35
    		Inhibitor
    KRAS inhibitor-35 (compound 72) is a KRAS inhibitor, with IC50 of 2 nM. KRAS inhibitor-35 can be used in tumor research.
    KRAS inhibitor-35
  • HY-143591
    KRAS G12C inhibitor 38
    		Inhibitor
    KRAS G12C inhibitor 38 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 38 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129820A1, compound 171).
    KRAS G12C inhibitor 38
  • HY-176787
    KRAS G12C Ligand-Linker Conjugates 1
    		Inhibitor
    KRAS G12C Ligand-Linker Conjugates 1 is a conjugate of KRASG12C ligand and linker, which can be used in the synthesis of PROTAC YF135 (HY-144323).
    KRAS G12C Ligand-Linker Conjugates 1
  • HY-153674
    PROTAC SOS1 degrader-4
    		Degrader
    PROTAC SOS1 degrader-4 (compound 10) is a potent SOS1 degrader. PROTAC SOS1 degrader-4 shows antiproliferative activity.
    PROTAC SOS1 degrader-4
  • HY-174306
    MARY1
    		Inhibitor
    MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM (human 5-HT2BR). MARY1 induces renal mitochondrial biogenesis (MB) and enhances renal mitochondrial function by increasing mitochondrial respiratory capacity, mitochondrial protein levels, and mitochondrial number in renal proximal tubular cells (RPTCs). MARY1 induces MB through 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK cell signaling pathways in RPTCs. MARY1 can be used to study renal diseases associated with metabolic and mitochondrial dysfunction.
    MARY1
  • HY-146476
    KRAS inhibitor-18
    		Inhibitor
    KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC50 of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC50s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-18
  • HY-124161
    SCH54292
    		Inhibitor
    SCH54292 is a potent Ras-GEF interaction inhibitor with IC50 of 0.7 μM.
    SCH54292
  • HY-168480
    SOS2 ligand 1
    		Ligand
    SOS2 ligand 1(compound 2) is a selective ligand of son of sevenless 2 (SOS2) with an KD value of 4.6 µM.
    SOS2 ligand 1
  • HY-112666
    Farnesyl thiosalicylic acid amide
    		Inhibitor
    Farnesyl thiosalicylic acid amide (FTS-A) is an orally active derivative of farnesyl thiosalicylic acid (HY-14754). Farnesyl thiosalicylic acid amide reduces Ras-GTP levels and inhibits cell growth with IC50s of 20 and 10 μM for Panc-1 and U87 cells, respectively. Farnesyl thiosalicylic acid amide can be used for the research of cancer.
    Farnesyl thiosalicylic acid amide
  • HY-115739
    RTIL 13
    		Inhibitor
    RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 μM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively.
    RTIL 13
  • HY-152951
    Palmostatin M
    		Modulator
    Palmostatin M is a Ras signaling modulator that targets acyl-protein thioesterase 1 (APT1) and 2 (APT2) in cells, with an IC50 of 2.5 nM for APT1. Palmostatin M interferes with the depalmitoylation cycle of Ras and downregulates the overall Ras signaling pathway. Palmostatin M can be used in cancer-related research.
    Palmostatin M
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.